newsfilter
← Latest News
GlobeNewswire·

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich's ataxia (FA)